Literature DB >> 27646944

Is Participation in Cancer Phase I Trials Really Therapeutic?

Jonathan Kimmelman1.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27646944      PMCID： PMC5321666          DOI： 10.1200/JCO.2016.67.9902

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  40 in total

1.  How valid are claims for synergy in published clinical studies?

Authors:  A Ocana; E Amir; C Yeung; B Seruga; I F Tannock
Journal:  Ann Oncol       Date:  2012-02-07       Impact factor: 32.976

2.  Presentation and subsequent publication rates of phase I oncology clinical trials.

Authors:  Luis H Camacho; Jennifer Bacik; Alexander Cheung; David R Spriggs
Journal:  Cancer       Date:  2005-10-01       Impact factor: 6.860

3.  American Society of Clinical Oncology policy statement update: the critical role of phase I trials in cancer research and treatment.

Authors:  Jeffrey S Weber; Laura A Levit; Peter C Adamson; Suanna Bruinooge; Howard A Burris; Michael A Carducci; Adam P Dicker; Mithat Gönen; Stephen M Keefe; Michael A Postow; Michael A Thompson; David M Waterhouse; Susan L Weiner; Lynn M Schuchter
Journal:  J Clin Oncol       Date:  2014-12-15       Impact factor: 44.544

4.  Research ethics. Beyond access vs. protection in trials of innovative therapies.

Authors:  Alex John London; Jonathan Kimmelman; Marina Elena Emborg
Journal:  Science       Date:  2010-05-14       Impact factor: 47.728

5.  Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials.

Authors:  Thomas G Roberts; Bernardo H Goulart; Lee Squitieri; Sarah C Stallings; Elkan F Halpern; Bruce A Chabner; G Scott Gazelle; Stan N Finkelstein; Jeffrey W Clark
Journal:  JAMA       Date:  2004-11-03       Impact factor: 56.272

6.  Risks and benefits of phase 1 oncology trials, 1991 through 2002.

Authors:  Elizabeth Horstmann; Mary S McCabe; Louise Grochow; Seiichiro Yamamoto; Larry Rubinstein; Troy Budd; Dale Shoemaker; Ezekiel J Emanuel; Christine Grady
Journal:  N Engl J Med       Date:  2005-03-03       Impact factor: 91.245

Review 7.  Terminal illness and access to Phase 1 experimental agents, surgeries and devices: reviewing the ethical arguments.

Authors:  Udo Schüklenk; Christopher Lowry
Journal:  Br Med Bull       Date:  2008-12-03       Impact factor: 4.291

8.  Ethics of phase 1 oncology studies: reexamining the arguments and data.

Authors:  Manish Agrawal; Ezekiel J Emanuel
Journal:  JAMA       Date:  2003-08-27       Impact factor: 56.272

Review 9.  Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy.

Authors:  A Italiano; C Massard; R Bahleda; A-L Vataire; E Deutsch; N Magné; J-P Pignon; G Vassal; J-P Armand; J-C Soria
Journal:  Ann Oncol       Date:  2007-11-27       Impact factor: 32.976

Review 10.  Placebo effects in oncology.

Authors:  Gisèle Chvetzoff; Ian F Tannock
Journal:  J Natl Cancer Inst       Date:  2003-01-01       Impact factor: 13.506
View more
  13 in total

1.  Ethical Challenges in Pediatric Oncology Care and Clinical Trials.

Authors:  Daniel J Benedetti; Jonathan M Marron
Journal:  Recent Results Cancer Res       Date:  2021

2.  Before Consent: Qualitative Analysis of Deliberations of Patients With Advanced Cancer About Early-Phase Clinical Trials.

Authors:  Sarah B Garrett; Thea M Matthews; Corey M Abramson; Christopher J Koenig; Fay J Hlubocky; Christopher K Daugherty; Pamela N Munster; Daniel Dohan
Journal:  JCO Oncol Pract       Date:  2019-10-11

3.  Investigator Disclosure and Advanced Cancer Patient Understanding of Informed Consent and Prognosis in Phase I Clinical Trials.

Authors:  Fay J Hlubocky; Nancy E Kass; Debra Roter; Susan Larson; Kristen E Wroblewski; Jeremy Sugarman; Christopher K Daugherty
Journal:  J Oncol Pract       Date:  2018-05-22       Impact factor: 3.840

4.  Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trials.

Authors:  Dai Chihara; Ruitao Lin; Christopher R Flowers; Shanda R Finnigan; Lisa M Cordes; Yoko Fukuda; Erich P Huang; Larry V Rubinstein; Loretta J Nastoupil; S Percy Ivy; James H Doroshow; Naoko Takebe
Journal:  Lancet       Date:  2022-08-13       Impact factor: 202.731

5.  Trends in Grade 5 Toxicity and Response in Phase I Trials in Hematologic Malignancy: 20-Year Experience From the Cancer Therapy Evaluation Program at the National Cancer Institute.

Authors:  Dai Chihara; Erich P Huang; Shanda R Finnigan; Lisa M Cordes; Nebojsa Skorupan; Yoko Fukuda; Larry V Rubinstein; S Percy Ivy; James H Doroshow; Loretta J Nastoupil; Christopher R Flowers; Naoko Takebe
Journal:  J Clin Oncol       Date:  2022-03-09       Impact factor: 50.717

6.  Proportion of Patients in Phase I Oncology Trials Receiving Treatments That Are Ultimately Approved.

Authors:  Sean X Zhang; Dean Fergusson; Jonathan Kimmelman
Journal:  J Natl Cancer Inst       Date:  2020-09-01       Impact factor: 13.506

Review 7.  Phase I trials as valid therapeutic options for patients with cancer.

Authors:  Jacob J Adashek; Patricia M LoRusso; David S Hong; Razelle Kurzrock
Journal:  Nat Rev Clin Oncol       Date:  2019-09-02       Impact factor: 66.675

8.  Reaffirming and Clarifying the American Society of Clinical Oncology's Policy Statement on the Critical Role of Phase I Trials in Cancer Research and Treatment.

Authors:  Jeffrey S Weber; Laura A Levit; Peter C Adamson; Suanna S Bruinooge; Howard A Burris; Michael A Carducci; Adam P Dicker; Mithat Gönen; Stephen M Keefe; Michael A Postow; Michael A Thompson; David M Waterhouse; Susan L Weiner; Lynn M Schuchter
Journal:  J Clin Oncol       Date:  2016-11-28       Impact factor: 44.544

Review 9.  Bringing a genomic perspective to the safety of drug treatment in oncology.

Authors:  Federico Innocenti
Journal:  F1000Res       Date:  2017-03-29

10.  Risk and surrogate benefit for pediatric Phase I trials in oncology: A systematic review with meta-analysis.

Authors:  Marcin Waligora; Malgorzata M Bala; Magdalena Koperny; Mateusz T Wasylewski; Karolina Strzebonska; Rafał R Jaeschke; Agnieszka Wozniak; Jan Piasecki; Agnieszka Sliwka; Jerzy W Mitus; Maciej Polak; Dominika Nowis; Dean Fergusson; Jonathan Kimmelman
Journal:  PLoS Med       Date:  2018-02-20       Impact factor: 11.069
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.